Kombiglyze XR (Saxagliptin + Metformin XR Fixed Dose Combination) Regulatory Postmarketing Surveillance
Phase of Trial: Phase IV
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Saxagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.